12 November 2020  
EMA/CHMP/585170/2020  
Committee for Medicinal Products for Human Use (CHMP) 
Summary of opinion1 (post authorisation) 
Pradaxa 
dabigatran etexilate 
On 12 November 2020, the Committee for Medicinal Products for Human Use (CHMP) adopted a positive 
opinion recommending a change to the terms of the marketing authorisation for the medicinal product 
Pradaxa. The marketing authorisation holder for this medicinal product is Boehringer Ingelheim 
International GmbH. 
The CHMP adopted a new pharmaceutical form and strength – coated granules (20 mg, 30 mg, 40 mg, 50 
mg, 110 mg, 150 mg) and powder and solvent for oral solution (6.25 mg/ml) – together with a new 
indication as follows: 2 
Treatment of VTE and prevention of recurrent VTE in paediatric patients from birth to 
less than 18 years of age. 
For age appropriate dose forms, see section 4.2. 
The CHMP also adopted this indication for the 75 mg, 110mg and 150 mg strength of the already 
authorised hard capsules form as follows:2 
Pradaxa 75 mg: 
Primary prevention of venous thromboembolic events (VTE) in adult patients who have undergone 
elective total hip replacement surgery or total knee replacement surgery. 
Treatment of VTE and prevention of recurrent VTE in paediatric patients from birth to 
less than 18 years of age. 
For age appropriate dose forms, see section 4.2. 
Pradaxa 110 mg: 
Primary prevention of venous thromboembolic events (VTE) in adult patients who have undergone 
1 Summaries of positive opinion are published without prejudice to the Commission decision, which will normally be issued 67 
days from adoption of the opinion 
2 New text in bold, , removed text as strikethrough 
Official address  Domenico Scarlattilaan 6  ●  1083 HS Amsterdam  ●  The Netherlands 
Address for visits and deliveries  Refer to www.ema.europa.eu/how-to-find-us 
Send us a question  Go to www.ema.europa.eu/contact   Telephone +31 (0)88 781 6000 
An agency of the European Union  
© European Medicines Agency, 2020. Reproduction is authorised provided the source is acknowledged. 
 
elective total hip replacement surgery or total knee replacement surgery. 
Prevention of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation 
(NVAF), with one or more risk factors, such as prior stroke or transient ischemic attack (TIA); age 
≥75 years; heart failure (NYHA Class ≥II); diabetes mellitus; hypertension. 
Treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE), and prevention of 
recurrent DVT and PE in adults 
Treatment of VTE and prevention of recurrent VTE in paediatric patients from birth to 
less than 18 years of age. 
For age appropriate dose forms, see section 4.2. 
Pradaxa 150 mg: 
Prevention of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation 
(NVAF), with one or more risk factors, such as prior stroke or transient ischemic attack (TIA); age 
≥75 years; heart failure (NYHA Class ≥II); diabetes mellitus; hypertension. 
Treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE), and prevention of 
recurrent DVT and PE in adults  
Treatment of venous thromboembolic events (VTE) and prevention of recurrent VTE in 
paediatric patients from birth to less than 18 years of age. 
For age appropriate dose forms, see section 4.2 
The CHMP also adopted the new contraindication for all the above strengths of hard capsules as follows: 
Patients with sSevere renal impairment (CrCL <30 mL/min) in adult patients 
• 
•  eGFR <50 mL/min/1.73m2 in paediatric patients 
Detailed recommendations for the use of this product will be described in the updated summary of 
product characteristics (SmPC), which will be published in the revised European public assessment report 
(EPAR), and will be available in all official European Union languages after a decision on this change to 
the marketing authorisation has been granted by the European Commission. 
Pradaxa  
EMA/CHMP/585170/2020 
Page 2/2 
 
  
  
 
 
 
